TD Cowen Increases DaVita (NYSE:DVA) Price Target to $150.00

DaVita (NYSE:DVA) had its price objective lifted by TD Cowen from $139.00 to $150.00 in a report published on Wednesday morning, Benzinga reports. TD Cowen currently has a hold rating on the stock.

Several other brokerages have also commented on DVA. Truist Financial raised their price objective on DaVita from $135.00 to $150.00 and gave the company a hold rating in a research report on Wednesday, May 15th. Barclays lifted their price target on DaVita from $133.00 to $150.00 and gave the stock an equal weight rating in a research report on Monday, May 6th. Finally, StockNews.com downgraded DaVita from a strong-buy rating to a buy rating in a report on Saturday, June 8th. Three analysts have rated the stock with a hold rating and two have issued a buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of Hold and an average target price of $146.00.

DaVita Stock Down 3.6 %

Shares of DaVita stock opened at $137.32 on Wednesday. The company has a debt-to-equity ratio of 7.95, a quick ratio of 1.37 and a current ratio of 1.43. DaVita has a 52-week low of $71.51 and a 52-week high of $147.93. The stock has a market capitalization of $12.04 billion, a price-to-earnings ratio of 15.60, a P/E/G ratio of 1.10 and a beta of 0.87. The company’s 50 day moving average price is $140.63 and its 200-day moving average price is $131.21.

DaVita (NYSE:DVA) last announced its quarterly earnings results on Thursday, May 2nd. The company reported $2.38 EPS for the quarter, topping analysts’ consensus estimates of $1.95 by $0.43. DaVita had a return on equity of 68.52% and a net margin of 6.61%. The company had revenue of $3.07 billion during the quarter, compared to analyst estimates of $3.03 billion. During the same quarter last year, the firm posted $1.58 earnings per share. The firm’s revenue was up 6.9% on a year-over-year basis. Equities research analysts forecast that DaVita will post 9.62 EPS for the current year.

Insider Activity at DaVita

In related news, Director Barbara J. Desoer sold 5,030 shares of the business’s stock in a transaction that occurred on Friday, May 10th. The stock was sold at an average price of $138.81, for a total value of $698,214.30. Following the transaction, the director now directly owns 10,954 shares of the company’s stock, valued at approximately $1,520,524.74. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. 2.00% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in DVA. Blue Trust Inc. raised its holdings in shares of DaVita by 58.6% during the 2nd quarter. Blue Trust Inc. now owns 211 shares of the company’s stock worth $29,000 after acquiring an additional 78 shares in the last quarter. Newbridge Financial Services Group Inc. purchased a new stake in DaVita during the 4th quarter valued at $30,000. Principal Securities Inc. bought a new position in DaVita in the 4th quarter valued at $37,000. Family Firm Inc. bought a new position in DaVita in the 2nd quarter valued at $43,000. Finally, Versant Capital Management Inc grew its position in shares of DaVita by 90.6% during the 2nd quarter. Versant Capital Management Inc now owns 326 shares of the company’s stock worth $45,000 after buying an additional 155 shares in the last quarter. 90.12% of the stock is owned by hedge funds and other institutional investors.

DaVita Company Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.